-
Introduction and geographic availability of new antibiotics approved between ...
Background Despite the urgent need for new, effective antibiotics, few antibiotics of value have entered the market during the past decades. Therefore, incentives have been... -
How long do new medicines take to reach Canadian patients after companies fil...
Introduction Studies of the delay between when companies file a New Drug Submission (NDS) and when drugs reach Canadian patients typically focus on the time in the regulatory... -
Industrial perceptions of medicines regulatory harmonization in the East Afri...
Background Medicines regulatory harmonization has been recommended as one way to improve access to quality-assured medicines in low- and middle-income countries. The rationale... -
Association between commercial funding of Canadian patient groups and their v...
Background Patient groups represent the interest of their members when it comes to drug funding. Many patient groups receive grants from pharmaceutical companies that make... -
Prevalence of clinical trial status discrepancies: A cross-sectional study of...
© 2018 Fleminger, Goldacre. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution,...
